32 scientific abstracts reflect ongoing commitment to improving outcomes for people living with epilepsies Data include the use of FINTEPLA® (fenfluramine)1 oral solution in seizures associated...

SK Life Science will also host the "Prioritizing Seizure Treatments Through Real-World Patient Case Studies Symposium," an expert led panel to advance the discussion regarding the unmet need for...

Eisai Inc. presented analyses of the ELEVATE study of its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2021 American Epilepsy Society (AES) Annual Meeting. ELEVATE was a...

Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy Society (AES) Annual Meeting to be held from December...

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders,...